Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ohio's Proposed Ban On Sales Marks Kratom Industry's Latest Battlefront

Executive Summary

Ohio Board of Pharmacy proposes placing into Schedule I kratom constituent ingredients mitragynine and 7-hydroxymitragynine, a change that would prohibit kratom sales in the state. The board's findings "parrot the false propaganda" of FDA in its "crusade to ban kratom," says the American Kratom Association.

Advertisement

Related Content

Health, Beauty And Wellness News: NPA On NIS, AHPA JAMA Letter, Zero Recall Two
Opioid Withdrawal Treatment Claims Spur FDA's Latest Kratom Warnings
FDA's Opioid Label For Kratom Called Misbranding By Marketers
DEA Proposal To Schedule Kratom Stirs Wave Of Opposition

Topics

Advertisement
UsernamePublicRestriction

Register

RS121859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel